2018, Vol. 1, Issue 1, Part A

Methods: An examination that looks ahead and examines parallels. The study was carried out in the Department of Community Medicine, Tagore Medical College, located in Chennai, Tamil Nadu, India. The study was done from January 2017 to December 2017. The current study involved the participation of 50 children with thalassemia who had undergone several transfusions and were receiving daily treatment with iron chelation. The study included children with thalassemia who had undergone several blood transfusions and were undergoing daily iron chelation therapy.

Results:The current study included 50 children with thalassemia who had received multiple blood transfusions. For a duration of 12 months, they received daily iron chelation therapy with either defer prone alone, deferasirox alone, or a combination of the two. The participants received the following daily treatments: Deferiprone alone, Deferasirox alone, and a combination of Deferiprone and Deferasirox constituted the treatment groups.

Conclusion: This study concluded that deferiprone and deferasirox were effective and safe when administered alone in children with thalassemia who had received several transfusions.